Chronic pain associated with inflammation is a major clinical problem, but the underlying mechanisms are incompletely understood. Recently, we reported that GRK2 +/À mice with a $50% reduction of GRK2 develop prolonged hyperalgesia following a single intraplantar injection of the pro-inflammatory cytokine interleukin-1b (IL-1b). Here we show that spinal microglia/macrophage GRK2 is reduced during chronic inflammation-induced hyperalgesia. Next, we applied CRE-Lox technology to create mice with low GRK2 in microglia/macrophages/granulocytes (LysM-GRK2 f/+ ), or sensory neurons or astrocytes. Only mice deficient in microglial/macrophage/granulocyte GRK2 display prolonged IL-1b-induced hyperalgesia that lasts up to 8 days. Two days after intraplantar IL-1b, increased microglial/macrophage activity occurs in the lumbar but not thoracic spinal cord of GRK2-deficient mice. Intrathecal pre-treatment with minocycline, an inhibitor of microglia/macrophage activation, accelerates resolution of hyperalgesia independent of genotype and prevents transition to chronic hyperalgesia in GRK2 +/À mice. Ongoing hyperalgesia in GRK2 +/À mice is reversed by minocycline administration at days 1 and 2 after IL-1b injection. Similarly, IL-1b-induced hyperalgesia in LysM-GRK2 f/+ mice is attenuated by intrathecal administration of anti-CX3CR1 to abrogate fractalkine signaling, the p38 inhibitor SB239063 and the IL-1 antagonist IL-1ra. These data establish that chronic inflammatory hyperalgesia is associated with reduced GRK2 in microglia/macrophages and that low GRK2 in these cells is sufficient to markedly prolong hyperalgesia after a single intraplantar injection of IL-1b. Ongoing hyperalgesia is maintained by spinal microglial/ macrophage activity, fractalkine signaling, p38 activation and IL-1 signaling. We propose that chronic inflammation decreases spinal microglial/macrophage GRK2, which prevents silencing of microglia/macrophage activity and thereby contributes to prolonged hyperalgesia. Ó
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Introduction
Pain associated with inflammation is an important clinical issue and can persist long after resolution of inflammation [20, 34] . Peripheral inflammation increases the response to painful stimuli via direct actions of inflammatory mediators such as interleukin1b (IL-1b) on primary sensory neurons [1, 12, 34] . This peripheral sensitization rapidly but transiently increases excitability of primary nociceptors and leads to a transient increase in the response to noxious stimulation [12] . Modulation of inflammatory hyperalgesia also takes place at the level of the spinal cord, and glial cells have been implicated in this process [6, 23] . However, the neurobiological mechanisms underlying inflammation-associated pain have only begun to be unraveled. Very little is currently known about the intra-and intercellular pathways that contribute to resolution of inflammatory hyperalgesia.
G protein-coupled receptor kinase 2 (GRK2) belongs to a family of seven G protein-coupled receptor kinases [28, 32] . GRK2 phosphorylates agonist-activated G protein-coupled receptors (GPCRs), leading to receptor desensitization and internalization [32, 39] . GRK2 can also interact with elements of several intracellular signaling pathways, including Akt, MEK1/2, phosphoinositide-3 kinase (PI3 kinase) and p38 MAPK, as well as various cytoskeletal elements [27, 33] . These two pathways allow GRK2 to regulate intracellular signaling not only in response to GPCR activation but also independent of GPCRs. An example of this last mechanism is the enhanced in vitro cytokine response of macrophages or
